RGEN - Repligen Corporation
| Previous Close | 92.66 |
| Open | 92.86 |
| Bid | 92.90 x 800 |
| Ask | 93.24 x 800 |
| Day's Range | 91.87 - 93.51 |
| 52 Week Range | 48.26 - 99.25 |
| Volume | 45,219 |
| Avg. Volume | 593,157 |
| Market Cap | 4.628B |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | 163.71 |
| EPS (TTM) | 0.57 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 105.29 |
- Motley Fool
3 Growth Stocks for In-the-Know Investors
Investors looking to grow their nest egg should give these three stocks a closer look.
- Zacks
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
- Motley Fool
Repligen Grows Revenue 48% in Q2
The bioprocess leader keeps growing at an incredible pace thanks to acquisitions and surging customer demand.
- Simply Wall St.
With A 3.0% Return On Equity, Is Repligen Corporation (NASDAQ:RGEN) A Quality Stock?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Thomson Reuters StreetEvents
Edited Transcript of RGEN earnings conference call or presentation 1-Aug-19 12:30pm GMT
Q2 2019 Repligen Corp Earnings Call
- Zacks
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.
- Zacks
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
Motley FoolRepligen (RGEN) Q2 2019 Earnings Call Transcript
RGEN earnings call for the period ending June 30, 2019.
- Zacks
Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
- Zacks
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
- GlobeNewswire
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growthRaises revenue guidance to $264-$268 million for full year 2019,.
- Zacks
Powell Gives Space for Growth, Market Overreacts: 5 Picks
Although market participants were expecting a quarter percentage point of cut, they were taken aback by Fed Chair Jerome Powell's comment that this rate cut is "in the nature of a mid-cycle adjustment to policy."
- Zacks
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
- Zacks
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
- Zacks
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
- Zacks
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Repligen to Report Second Quarter 2019 Financial Results
Repligen Corporation (RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1, 2019. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website.
- Zacks
Is a Beat in Store for Repligen (RGEN) This Earnings Season?
On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.
- GlobeNewswire
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
Repligen Corporation (RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $138.1 million, and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. The offering of the Shares (the “Shares Offering”) is expected to result in approximately $130.7 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen.
- Zacks
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
Is (RGEN) Outperforming Other Medical Stocks This Year?
- Zacks
NuCana Initiates Dosing in Phase I Study for Solid Tumors
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
- Zacks
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
- GlobeNewswire
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
Repligen Corporation (RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $120 million, and $250 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”). In addition, Repligen has granted the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to an additional 207,000 Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37.5 million aggregate principal amount of additional Notes solely to cover over-allotments.
- GlobeNewswire
Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
Repligen Corporation (RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in shares of its common stock (the “Shares”) and $250,000,000 aggregate principal amount of convertible senior notes due 2024 (the “Notes”). In addition, Repligen expects to grant the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to $15,000,000 of additional Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37,500,000 aggregate principal amount of additional Notes solely to cover over-allotments. The Notes will be senior, unsecured obligations of Repligen, and interest will be payable semi-annually in arrears.
- Simply Wall St.
Repligen Corporation (NASDAQ:RGEN): Financial Strength Analysis
Mid-caps stocks, like Repligen Corporation (NASDAQ:RGEN) with a market capitalization of US$4.1b, aren’t the focus of...
